— News and commentary from the world of gastroenterology and hepatology

by Ian Ingram, Managing Editor, MedPage Today

September 3, 2026

• 2 min read

The FDA said it expanded approval of the interleukin (IL)-12/23 antagonist ustekinumab (Stelara) to include treatment of moderately to severely active ulcerative colitis in children as young as 2 years.